Cognoa, a digital health company developing software tools for children with autism and other behavioral health conditions and their families, signaled today that it will be moving ahead with a De Novo FDA regulatory submission for its digital autism spectrum disorder (ASD) diagnostic.
The tool, which received a Breakthrough Device Designation from the agency in late 2018, is designed to help...